Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
Publication Date: August 8, 2016
Key Points
Key Points
- Nearly 75% of women with ovarian cancer are diagnosed with advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIIC or IV) at presentation.
- Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
- However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
- This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Assessment
Assessment
...en with suspected stage IIIC or IV invasi...
...ary clinical evaluation should include a computed...
Treatment
...reatment
...1. Risk Factors for Perioperative Morbid...
...ave a high perioperative risk profile...
...hat women are not eligible for medical...
...women who are fit for PCS, with pot...
...with a high likelihood of achieving cytor...
...omen who are fit for PCS but are deemed unlike...
...NACT is delivered, all patients should hav...
...or NACT, a platinum/taxane doublet...
...d surgery following three or four cyc...
Patients with progressive disease on NACT...
...Evaluation and Treatment of Women With Susp...